ENDRA Life Sciences (NDRA) Research & Development (2016 - 2026)

ENDRA Life Sciences has disclosed Research & Development across 11 years of filings, most recently posting $776410.0 for Q1 2026.

• In Q1 2026, Research & Development rose 46.86% year-over-year to $776410.0; the TTM figure through Mar 2026 stood at $2.1 million (down 21.65% YoY), while the FY2025 annual figure was $1.8 million, down 42.01% from the prior year.
• Research & Development rose to $776410.0 in Q1 2026, from $508137.0 in the prior quarter.
• Over the last five years, Research & Development for NDRA reached as high as $1.8 million in Q2 2022 and fell as low as $381061.0 in Q2 2025.
• The 5-year median for Research & Development is $794444.0 (2024), against an average of $1.0 million.
• Annual changes were most pronounced in 2022 — Research & Development soared 55.99% — and 2023, when it sank 65.17%.
• A 5-year view of Research & Development shows it stood at $1.7 million in 2022, then slumped by 65.17% to $579350.0 in 2023, then gained by 10.12% to $637957.0 in 2024, then decreased by 20.35% to $508137.0 in 2025, then jumped by 52.8% to $776410.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $776410.0, $508137.0, and $432113.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.